4basebio UK Societas (4BB) Price & Analysis

Compare

7 Followers

4BB Stock Chart & Stats

Day’s Range― - ―

52-Week Range940.00p - 1,550.00p

Previous CloseN/A

Volume812.00

Average Volume (3M)1.25K

Market Cap

£152.53M

Enterprise Value135.33M

Total Cash (Recent Filing)£34.60M

Total Debt (Recent Filing)£15.22M

Price to Earnings (P/E)―

Beta0.05

Next Earnings

Sep 26, 2025

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.52

Shares Outstanding15,509,393

10 Day Avg. Volume1,660

30 Day Avg. Volume1,255

Financial Highlights & Ratios

PEG Ratio0.90

Price to Book (P/B)4.82

Price to Sales (P/S)0.00

P/FCF Ratio-13.57

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

£1,600.00

Price Target Upside62.44% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

4basebio UK Societas News

PremiumCompany Announcements

4basebio Appoints Dr. Manja Boerman as Executive Chair Amid Board Changes

15d ago

PremiumCompany Announcements

4basebio UK Societas Announces Change in Voting Rights

21d ago

PremiumCompany Announcements

4basebio Announces Change in Voting Rights Structure

21d ago

PremiumCompany Announcements

4basebio PLC Announces AGM Results with Key Resolutions Amended

25d ago

PremiumCompany Announcements

4basebio PLC Announces Exercise of Options and Share Issuance

28d ago

PremiumCompany Announcements

4basebio UK Societas Announces Change in Major Holdings

1M ago

PremiumCompany Announcements

DELPHI Unternehmensberatung Increases Stake in 4basebio

1M ago

PremiumCompany Announcements

4basebio PLC Reports Strong 2024 Growth and Strategic Advancements

2M ago

See All GB:4BB News

See All News >

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

11.95% Insiders

―

Mutual Funds

― Other Institutional Investors

88.05% Public Companies and

Individual Investors

Detailed Ownership Overview >

4BB FAQ

What was 4basebio UK Societas’s price range in the past 12 months?

4basebio UK Societas lowest share price was 940.00p and its highest was 1550.00p in the past 12 months.

What is 4basebio UK Societas’s market cap?

4basebio UK Societas’s market cap is £152.53M.

When is 4basebio UK Societas’s upcoming earnings report date?

4basebio UK Societas’s upcoming earnings report date is Sep 26, 2025 which is in 65 days.

How were 4basebio UK Societas’s earnings last quarter?

4basebio UK Societas released its earnings results on May 07, 2025. The company reported -0.52p earnings per share for the quarter, missing the consensus estimate of N/A by -0.52p.

Is 4basebio UK Societas overvalued?

According to Wall Street analysts 4basebio UK Societas’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does 4basebio UK Societas pay dividends?

4basebio UK Societas does not currently pay dividends.

What is 4basebio UK Societas’s EPS estimate?

4basebio UK Societas’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does 4basebio UK Societas have?

4basebio UK Societas has 15,509,393 shares outstanding.

What happened to 4basebio UK Societas’s price movement after its last earnings report?

4basebio UK Societas reported an EPS of -0.52p in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of 4basebio UK Societas?

Currently, no hedge funds are holding shares in GB:4BB

4basebio UK Societas Stock Smart Score

Underperform

Fundamentals

Return on Equity

-95.28%

Trailing 12-Months

Asset Growth

275.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

4basebio UK Societas

4basebio UK Societas (4BB) is a biotechnology company focused on the development and production of synthetic DNA for use in gene therapies, gene editing, and vaccines. The company operates in the life sciences sector, leveraging its proprietary technologies to provide high-quality genetic materials that enable advancements in personalized medicine and biopharmaceutical research.

4BB Stock 12 Month Forecast

Average Price Target

1,600.00p

▲(62.44%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1074":"1,074p","1601":"1,601p","1205.75":"1,205.8p","1337.5":"1,337.5p","1469.25":"1,469.3p"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">1.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">1.60K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1600,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">1.60K</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1074,1205.75,1337.5,1469.25,1601],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"May<br/>2025","25":"May<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1125,1161.5384615384614,1198.076923076923,1234.6153846153845,1271.1538461538462,1307.6923076923076,1344.2307692307693,1380.7692307692307,1417.3076923076924,1453.8461538461538,1490.3846153846155,1526.923076923077,1563.4615384615386,{"y":1600,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1125,1161.5384615384614,1198.076923076923,1234.6153846153845,1271.1538461538462,1307.6923076923076,1344.2307692307693,1380.7692307692307,1417.3076923076924,1453.8461538461538,1490.3846153846155,1526.923076923077,1563.4615384615386,{"y":1600,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1125,1161.5384615384614,1198.076923076923,1234.6153846153845,1271.1538461538462,1307.6923076923076,1344.2307692307693,1380.7692307692307,1417.3076923076924,1453.8461538461538,1490.3846153846155,1526.923076923077,1563.4615384615386,{"y":1600,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1075,"date":1714521600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1400,"date":1717200000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1550,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1500,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1450,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1390,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1260,"date":1730419200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1300,"date":1733011200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1210,"date":1735689600000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1200,"date":1738368000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1160,"date":1740787200000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1160,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1125,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >